Prostaglandin E2, an immunoactivator

Daiji Sakata, Chengcan Yao, Shuh Narumiya

Research output: Contribution to journalReview article

81 Citations (Scopus)

Abstract

Diseases caused by immune inflammation, such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease, are intractable diseases to which novel therapeutics are highly demanded. Prostaglandin (PG) E2 is the most ubiquitously produced PG with various actions. PGE2 has been traditionally regarded as an immunosuppressant based on its inhibition of T cell activation in vitro. However, in vivo relevance of the immunosuppressant action of PGE2 has remained obscure. Recently, several groups including ourselves have made unexpected findings that PGE2 facilitates expansion of the Th17 subset of T helper cells of both human and mouse through elevation of cAMP via PGE receptors EP2 and EP4. We have further found that PGE2 can induce and not suppress Th1 differentiation under certain conditions, again, through EP2 and EP4. Given the putative roles of these Th subsets in immune diseases such as the above, these findings suggest that, on the contrary to the traditional view, PGE2 functions as a mediator of immune inflammation. Consistently, administration of an EP4 antagonist could suppress disease progression and development of antigen-specific Th17 cells in mice subjected to experimental allergic encephalomyelitis and contact hypersensitivity. In this perspective, we review these findings and discuss the prospect of EP4 antagonists as immunomodulatory drugs.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalJournal of Pharmacological Sciences
Volume112
Issue number1
DOIs
Publication statusPublished - Feb 8 2010

Fingerprint

Immunologic Adjuvants
Dinoprostone
Immune System Diseases
Immunosuppressive Agents
Prostaglandin E Receptors
Th17 Cells
Inflammation Mediators
Autoimmune Experimental Encephalomyelitis
Contact Dermatitis
Helper-Inducer T-Lymphocytes
Crohn Disease
Multiple Sclerosis
Prostaglandins
Disease Progression
Rheumatoid Arthritis
Inflammation
T-Lymphocytes
Antigens
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Prostaglandin E2, an immunoactivator. / Sakata, Daiji; Yao, Chengcan; Narumiya, Shuh.

In: Journal of Pharmacological Sciences, Vol. 112, No. 1, 08.02.2010, p. 1-5.

Research output: Contribution to journalReview article

Sakata, Daiji ; Yao, Chengcan ; Narumiya, Shuh. / Prostaglandin E2, an immunoactivator. In: Journal of Pharmacological Sciences. 2010 ; Vol. 112, No. 1. pp. 1-5.
@article{f5c62efbac6a4b6880e1fef9794abe0f,
title = "Prostaglandin E2, an immunoactivator",
abstract = "Diseases caused by immune inflammation, such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease, are intractable diseases to which novel therapeutics are highly demanded. Prostaglandin (PG) E2 is the most ubiquitously produced PG with various actions. PGE2 has been traditionally regarded as an immunosuppressant based on its inhibition of T cell activation in vitro. However, in vivo relevance of the immunosuppressant action of PGE2 has remained obscure. Recently, several groups including ourselves have made unexpected findings that PGE2 facilitates expansion of the Th17 subset of T helper cells of both human and mouse through elevation of cAMP via PGE receptors EP2 and EP4. We have further found that PGE2 can induce and not suppress Th1 differentiation under certain conditions, again, through EP2 and EP4. Given the putative roles of these Th subsets in immune diseases such as the above, these findings suggest that, on the contrary to the traditional view, PGE2 functions as a mediator of immune inflammation. Consistently, administration of an EP4 antagonist could suppress disease progression and development of antigen-specific Th17 cells in mice subjected to experimental allergic encephalomyelitis and contact hypersensitivity. In this perspective, we review these findings and discuss the prospect of EP4 antagonists as immunomodulatory drugs.",
author = "Daiji Sakata and Chengcan Yao and Shuh Narumiya",
year = "2010",
month = "2",
day = "8",
doi = "10.1254/jphs.09R03CP",
language = "English",
volume = "112",
pages = "1--5",
journal = "Journal of Pharmacological Sciences",
issn = "1347-8613",
publisher = "Japanese Pharmacological Society",
number = "1",

}

TY - JOUR

T1 - Prostaglandin E2, an immunoactivator

AU - Sakata, Daiji

AU - Yao, Chengcan

AU - Narumiya, Shuh

PY - 2010/2/8

Y1 - 2010/2/8

N2 - Diseases caused by immune inflammation, such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease, are intractable diseases to which novel therapeutics are highly demanded. Prostaglandin (PG) E2 is the most ubiquitously produced PG with various actions. PGE2 has been traditionally regarded as an immunosuppressant based on its inhibition of T cell activation in vitro. However, in vivo relevance of the immunosuppressant action of PGE2 has remained obscure. Recently, several groups including ourselves have made unexpected findings that PGE2 facilitates expansion of the Th17 subset of T helper cells of both human and mouse through elevation of cAMP via PGE receptors EP2 and EP4. We have further found that PGE2 can induce and not suppress Th1 differentiation under certain conditions, again, through EP2 and EP4. Given the putative roles of these Th subsets in immune diseases such as the above, these findings suggest that, on the contrary to the traditional view, PGE2 functions as a mediator of immune inflammation. Consistently, administration of an EP4 antagonist could suppress disease progression and development of antigen-specific Th17 cells in mice subjected to experimental allergic encephalomyelitis and contact hypersensitivity. In this perspective, we review these findings and discuss the prospect of EP4 antagonists as immunomodulatory drugs.

AB - Diseases caused by immune inflammation, such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease, are intractable diseases to which novel therapeutics are highly demanded. Prostaglandin (PG) E2 is the most ubiquitously produced PG with various actions. PGE2 has been traditionally regarded as an immunosuppressant based on its inhibition of T cell activation in vitro. However, in vivo relevance of the immunosuppressant action of PGE2 has remained obscure. Recently, several groups including ourselves have made unexpected findings that PGE2 facilitates expansion of the Th17 subset of T helper cells of both human and mouse through elevation of cAMP via PGE receptors EP2 and EP4. We have further found that PGE2 can induce and not suppress Th1 differentiation under certain conditions, again, through EP2 and EP4. Given the putative roles of these Th subsets in immune diseases such as the above, these findings suggest that, on the contrary to the traditional view, PGE2 functions as a mediator of immune inflammation. Consistently, administration of an EP4 antagonist could suppress disease progression and development of antigen-specific Th17 cells in mice subjected to experimental allergic encephalomyelitis and contact hypersensitivity. In this perspective, we review these findings and discuss the prospect of EP4 antagonists as immunomodulatory drugs.

UR - http://www.scopus.com/inward/record.url?scp=75749088574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749088574&partnerID=8YFLogxK

U2 - 10.1254/jphs.09R03CP

DO - 10.1254/jphs.09R03CP

M3 - Review article

VL - 112

SP - 1

EP - 5

JO - Journal of Pharmacological Sciences

JF - Journal of Pharmacological Sciences

SN - 1347-8613

IS - 1

ER -